Table 3. Imaging, clinical laboratory and cause of death of COVID-19 patients.
| Imaging lung | n = 313 | % |
|---|---|---|
| Lung opacities | 171 | 54.6 |
| Lung consolidation | 103 | 32.9 |
| Thromboembolic events | 19 | 6.1 |
| Lung shadows | 11 | 3.5 |
| Lung lesions | 2 | 0.6 |
| Imaging Central Nervous System | n = 13 | % |
| Infarction/Ischemia | 4 | 30.8 |
| Clinical laboratory | Abnormal/Total reported | % |
| C-Reactive Protein | 92/101 | 91.0 |
| Ferritin | 30/36 | 83.3 |
| D-dimer | 114/137 | 83.2 |
| Lactate dehydrogenase | 80/100 | 80.0 |
| Interleukin-6 | 52/70 | 74.3 |
| Procalcitonin | 14/21 | 66.7 |
| Aspartate aminotransferase | 65/99 | 65.6 |
| Creatinine | 90/148 | 60.8 |
| Alanine aminotransferase | 44/88 | 50 |
| Creatine Kinase | 11/26 | 42.3 |
| Platelet | 19/102 | 18.6 |
| COVID-19 specified cause of death | n = 227 | % |
| Respiratory Failure | 161 | 70.9 |
| Multiorgan failure | 25 | 11.0 |
| Cardiac | 24 | 10.6 |
| COVID-19 | 16 | 7.0 |
| Pneumonia | 15 | 6.6 |
| Septic shock | 7 | 3.0 |
| Pulmonary Emboli | 5 | 2.2 |
| Gastrointestinal | 3 | 1.3 |
| Cerebral hemorrhage | 2 | 0.9 |
| Liver cirrhosis | 1 | 0.4 |
| Renal failure | 1 | 0.4 |
| Community deaths | n = 9 |